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Georgia, a country of 4.5 million people, has a high incidence of tuberculosis (TB) including drug resistant cases. Easy access
and inappropriate use of anti-TB drugs are risk factors for further development of multidrug resistant (MDR)-TB. We carried
out an investigation to assess the availability of over the counter anti-TB agents in pharmacies in Tbilisi. During February 2006,
15 pharmacies were randomly selected and the pharmacist at each store was interviewed. We found that all anti-TB medications
stocked by these pharmacies were available and sold without a prescription. All 15 pharmacies sold isoniazid, rifampicin, and
streptomycin; 13 (87%) of 15 pharmacies also sold pyrazinamide, ethambutol. Second line anti-TB drugs such as amikacin
and kanamycin (injectable agents) and older ﬂuoroquinolones (oﬂoxacin and ciproﬂoxacin) were available at 13 pharmacies
while newer generation ﬂuoroquinolones were less available(3 sold leovoﬂoxacin, none sold moxiﬂoxacin). The ease access and
availability of anti-TB agents is of a great concern given the high prevalence of TB including MDR-TB in Georgia. The potential
for misuse of these anti-TB drugs can lead to the development of further drug resistance. These drugs should only be available by
prescription in order to reduce the chance of amplifying drug resistance.
Copyright © 2009 Ketevan Kobaidze et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Background
Tuberculosis (TB) is an enormous global public health
problem with approximately 9 million new cases and 2
million deaths due to the disease each year [1]. The world-
wide emergence of drug-resistant TB has greatly threatened
global TB control eﬀorts. Multidrug resistant TB (MDR-TB)
deﬁnedasresistancetoatleastboth isoniazid andrifampin is
now widespread [2]. MDR-TB is particularly challenging to
treat and to be associated with high morbidity and mortality.
Recent reports have highlighted the emergence of extensively
drug resistant TB (XDR-TB, deﬁned as MDR strains which
are also resistant to a ﬂuoroquinolone and an injectable
drug such as amikacin, kanamycin, or capreomycin) which is
virtually untreatable [3, 4]. The World Health Organization
(WHO) global surveillance for anti–tuberculosis drug resis-
tance has found that the highest prevalence of drug resistant
TB including MDR-TB is in former Soviet republics [2].
Georgia, a country of 4.5 million people, located in
the Caucuses has a high incidence of TB as well as a high
prevalence of drug resistant TB. In 2005, a total of 6448 TB
cases were reported in Georgia; the incidence and prevalence
of TB was 97 cases and 147 cases per 100000 population,
respectively [5]. A recent population-based drug resistant
survey found that the prevalence of MDR-TB in Georgia
was ∼7% among newly diagnosed patients and 27% among
previously treated patients [6].
Inappropriate use of anti-tuberculosis drugs, inappro-
priate treatment regimens, failure to ensure adherence
by the delivery of therapy by directly observed therapy
(part of the WHO-recommended DOTS strategy), inter-
rupted supplies of drugs, and poor quality drugs are risk
factors for the emergence of MDR-TB [7]. In Georgia,
the National Tuberculosis Program (NTP) endorsed the
Directly Observed Therapy, Short-Course (DOTS) strategy
in 1997, but it has only been in the past few years that2 Interdisciplinary Perspectives on Infectious Diseases
Table 1: Availability of Antituberculosis Antibiotics at 15 Pharmacies in Tblisi, Georgia Over the Counter without a Prescription.
Product (n =number of pharma-
cies stocking product)
Dose Sale unit Country of manufacture Mean Price per sale Unit Mean price per daily dose
for a 70kg adult (USD)
Isoniazid (n = 15) 300 mg 100 pills Russia 2.06L/$1.12 $0.01




Ethambutol (n = 13) 400 mg 50 pills Russia 5.00L/$2.72 $0.16
10 pills Germany 2.00L/$1.09 $0.33
50 pills Ukraine 5.00L/$2.72 $0.16
Pyrazinamide(PZA) (n = 13) 500 mg 100 pills Slovenia 20.00L/$10.87 $0.33
Germany 20.00L/$10.87 $0.33
Streptomycin (n = 15) 1 gram 1 amp Russia 0.19L/$0.10 $0.10
Ukraine 0.21L/$0.11 $0.11
Amikacin (n = 13) 500mg 1 amp Italy 9.00L/$4.89 $9.78
250mg 1 amp Bulgaria 1.80L/$0.98 $3.92
500mg 1 amp USA 9.00L/$4.89 $9.78
Kanamycin (n = 13) 1 gram 1 amp Russia 0.30L/$0.16 $0.16
Ukraine 0.30L/$0.16 $0.16
Ciproﬂoxacin (n = 13) 500mg 10 pills Germany 51.00 L/$27.72 $8.31
10 pills India 1.50L/$0.82 $0.24
10 pills Bulgaria 3.80L/$2.07 $0.62
L – Lari, Georgian currency, at the time of the interview $1USD = 1.84L. Capreomycin, moxiﬂoxacin, gatiﬂoxacin, para-aminosalicylic acid (PAS),
ethionamide, and cycloserine were not available at any of the pharmacies.
substantial areas of Georgia have had DOTS implementa-
tion. Inappropriate use of anti-tuberculosis antibiotics is
associated with the emergence of resistance. Several authors
reported interesting data about over-the-counter availability
of anti-tuberculosis medications in private pharmacies in
Bolivia, Vietnam, Nepal, and India [8–11]. Over-the-counter
antibiotics including anti-tuberculosis agents are available
at pharmacies in Georgia as is the case in most other
resource limited areas. Easy access and inappropriate use
of these drugs are risk factors for further development of
drug resistant–TB in Georgia. Given the lack of data on
whichagentsareavailableoverthecounter,wecarriedoutan
investigation to assess availability, price, and source of anti-
TB agents available over the counter in pharmacies in Tbilisi,
Georgia.
2. Methods
A questionnaire was developed to survey the over-the-
counter availability of anti-TB agents at pharmacies in
Tbilisi, Georgia. During February 2006, 15 pharmacies in
Tbilisi, Georgia were randomly selected for assessment from
pharmacies listed in the Tbilisi “Yellow Pages” directory.
The pharmacist at each store was interviewed by one of the
authors (KK) and provided the current retail price of each
anti-TB antibiotic. They were also asked their opinion on
futureplansforsalesofthesedrugs.Datafromthecompleted
questionnaires were entered into Epi-Info (CDC, Atlanta,
Ga, USA) which was used to perform analyses.
3. Results
Allanti-TBmedicationsstockedbythese15pharmacieswere
available and sold without a prescription. The availability,
origin, and price are summarized in Table 1. First-line drugs
were readily available in pharmacies. All 15 pharmacies sold
isoniazid, rifampin, and streptomycin, and 13 (87%) of
15 pharmacies also stocked and sold pyrazinamide (PZA)
and ethambutol. A number of second-line drugs were also
available over the counter. Thirteen (87%) of 15 pharmacies
sold the injectable agents amikacin and kanamycin which are
preferred agents used in the treatment of MDR-TB. Fluo-
roquinolones were available at most pharmacies. Oﬂoxacin
and ciproﬂoxacin were available at 13 (87%) pharmacies
while newer-generation ﬂuoroquinolones were less available;
levoﬂoxacin was sold at 3 (20%) pharmacies and none car-
ried gatiﬂoxacin or moxiﬂoxacin. Other second-line drugs
including para-aminosalicylic acid (PAS), cycloserine, and
capreomycin were not available at any of the pharmacies.
The mean price for these drugs is shown in Table 1.P r i c e s
for the individual products were remarkably similar among
the pharmacy shops (data not shown). However, there were
noticeable diﬀerences in prices between brand manufactured
in Europe or the United States which were higher inInterdisciplinary Perspectives on Infectious Diseases 3
price than the same drug manufactured in Russia or India
(Table 1).
4. Discussion/Conclusions
We found that anti-TB drugs were widely available over the
counter without a prescription at pharmacies in Tbilisi, the
capital of Georgia. This included the universal availability
of isoniazid and rifampin, the two most important ﬁrst
line agents as well as most other ﬁrst line agents. In
addition, a number of the most important second-line
agents used to treat MDR-TB including injectable agents
(amikacin and kanamycin) and ﬂuoroquinolones were also
available at most pharmacies. The ease of availability of
these agents is of great concern given the high prevalence
of TB including MDR-TB in Georgia and the potential for
misuse of these antituberculosis drugs which can spawn
further drug resistance (including the development of XDR-
TB due to misuse of second-line drugs). At the time of the
survey, second-line drugs and treatment of MDR-TB were
not available through the Georgian National Tuberculosis
Program (NTP). In 2007, the Georgian NTP began pilot
projects for the treatment of MDR-TB and received approval
from the WHO Green Light Committee (GLC) to procure
second-line drugs which is being supported through a grant
from the Global Fund to Fight AIDS, Tuberculosis, and
Malaria. Given the gravity of TB and drug resistant TB in
Georgia, education of policy makers as well as public health
advocates, physicians, pharmacists, and the public about
the potential impact and misuse of anti-tuberculosis drugs
which are available over the counter without a prescription
is critical if a national policy is to be established to restrict
the sale of over the counter anti-TB drugs. Anti-tuberculosis
drugs should only be received by directly observed therapy
through the National Tuberculosis Program. When drugs
which can be used to treat TB are dispensed by pharmacists
(e.g., second-line drugs such as ﬂuroquinolones or amikacin
which are also used to treat bacterial infections), these
drugs should only be available by prescription in order to
reduce the chance of amplifying drug resistance through
inappropriate use of these agents.
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